Urolog. pro Praxi, 2001; 4: 145-149

Léčba karcinomu prostaty ohraničeného na prostatu

MUDr. Libor Šafařík CSc1, prof. MUDr. Jan Dvořáček DrSc1, doc. MUDr. Jaroslav Novák CSc1,2, MUDr. Květoslav Novák1
1 Urologická klinika 1. LF UK a VFN Praha
2 Urologické a Onkologické oddělení, Oblastní nemocnice Kladno, a. s., nemocnice Středočeského kraje

Keywords: organ-confined prostate cancer (OCD), radical prostatectomy, radiotherapy.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šafařík L, Dvořáček J, Novák J, Novák K. Léčba karcinomu prostaty ohraničeného na prostatu. Urol. praxi. 2001;2(4):145-149.

Práce podává přehled současných názorů na léčbu lokálně ohraničeného karcinomu prostaty v souvislostech s prognózou nemocných a morbiditou po kurativní léčbě. Jsou uvedeny i některé méně časté operační metody (brachyradioterapie, kryoterapie), které se v České republice zatím neprovádějí, především pro vysoké vstupní náklady.

Therapy of organ-confined prostate cancer

The article gives a current overview of therapeutic approaches to the organ-confined prostate cancer in connection with the prognosis and postoperative morbidity of the patients after curative therapy. There are described also less frequently used surgical methods (brachytherapy and cryotherapy), which have not been used in the Czech republic so far, mainly due to high initial costs.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ústav zdravotnických informací a statistiky, Národní onkologický registr ČR, 2001.
    2. American Cancer Society, Internet website, 2000.
    3. Black R. J., Bray F., Ferlay J., Parkin D. M.: Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer, 1997, 33, 1075-1107. Go to original source... Go to PubMed...
    4. Ústav zdravotnických informací a statistiky, Národní onkologický registr ČR, 2001.
    5. Enlund A., Pedersen K., Boeryd B., Varenhorst E.: Transrectal ultrasonography compared to histological assessment for local staging of prostatic carcinoma. Acta Radiol 1990, 31, 597-600. Go to original source... Go to PubMed...
    6. Schnall M. D., Imai Y., Tomaszewski J., Pollack H., Lenkinski R. E., Kressel H. Y.: Prostate cancer: local staging with endorectal surface coil MR imaging. Radiology 1991, 178, 797-802. Go to original source... Go to PubMed...
    7. Oyen R.H.: Imaging modalities in diagnosis and staging of carcinoma of the prostate. In: Carcinoma of the Prostate. Innovations in Management. Petrovich Z., Baert L., Brady L. W. et al. (eds). Springer Verlag Berlin, 1996, 65-96. Go to original source...
    8. Partin A. W., Yoo J., Pearson J. D., Chan D. W., Epstein J. I., Walsh P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol, 1993, 150, 110-114. Go to original source... Go to PubMed...
    9. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H: Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000 Nov; 164 (5): 1591-1595. Go to original source...
    10. Walsh P. C., Donker P. J.: Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982 Sep; 128 (3): 492-497. Go to original source... Go to PubMed...
    11. Gibbons R. P., Correa R. J. Jr., Brannon G. E., Weissman R. M.: Total prostatectomy for clinically localized prostatic cancer: Long-term results. J Urol, 1989, 141, 564-566. Go to original source... Go to PubMed...
    12. Guillonneau B., Cathelineau X., Barret E., Rozet F., Vallancien G.: Laparoscopic radical prostatectomy. Preliminary evaluation after 28 interventions. Presse Med 1998 Oct 17; 27 (31): 1570-1574. Go to PubMed...
    13. Jepsen J. V., Bruskewitz R. C.: Should the seminal vesicles be resected during radical prostatectomy? Urology 1998 Jan; 51 (1): 12-18. Go to original source... Go to PubMed...
    14. European Association of Urology Guidelines 2001, 21.
    15. Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., Walsh P. C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 May 5; 281 (17): 1591-1597. Go to original source... Go to PubMed...
    16. European Association of Urology Guidelines 2001, 18.
    17. Kuban D. A., El-Mahdi A. M., Schellhammer P. F.: Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiant Oncol Biol Phys 1995, 23, 307-316. Go to original source... Go to PubMed...
    18. Zagars G. K., Pollack A., von Eschenbach A. C.: Prognostic factors for clinically localized prostate carcinoma. Cancer, 1997, 79, 1370-1380. Go to original source...
    19. Kupelian P. A., Mohan D. S., Lyons J., Klein E. A., Reddy C. A.: Higher than standard radiation doses (or = 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000, 46, 567-574. Go to original source... Go to PubMed...
    20. Hanks G. E., Schultheiss T. E., Hanlon A. L., Hunt M., Lee W. R., Epstein B. E., Coia L. R.: Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997, 37, 543-550. Go to original source... Go to PubMed...
    21. Blasko J. C., Grimm P. D., Sylvester J. E., Badiozamani K. R., Hoak D., Cavanagh W.: Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys, 2000, 46, 839-850. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.